

**Mo-99 2015 TOPICAL MEETING ON
MOLYBDENUM-99 TECHNOLOGICAL DEVELOPMENT**

**AUGUST 31-SEPTEMBER 3, 2015
HILTON BOSTON BACK BAY
BOSTON, MASSACHUSETTS**

GE Healthcare Global Sourcing

Jessica Hinkle
GE Healthcare

Life Sciences Core Imaging and InVitro Diagnostics Sourcing
3350 North Ridge Ave., Arlington Heights IL 60004 – USA

ABSTRACT

GE Healthcare (GEHC) has been integrally involved in building and maintaining a stable Supply Chain for Molybdenum-99 (Mo-99) both as a manufacturer of Technetium-99 (Tc-99) generators, as well as a distributor of patient doses through GE's US radiopharmacies. GEHC continues to be a strong supporter of transitioning from HEU to LEU material. Today, we are actively working on validations in order to use Mo-99 generated from LEU in our Drytec generators. Additionally, a significant focus has been placed on ensuring our radiopharmacies have robust systems to adequately track the distribution of LEU doses as we begin to fully convert our pharmacies.

In order to ensure the continued reliable supply of this medical isotope, GE has contractual relationships with both Lantheus and Mallinckrodt, actively is communicating with customers to ensure they are aware of the impact associated with the shift to LEU and continues to support alternative technologies, which do not utilize HEU starting materials.

It is GE's priority to ensure awareness of the key challenges with the current Mo-99 Supply Chain, as well as mitigate to the best of our abilities any supply disruptions. We continue to invest in the future of Nuclear Medicine as well as work to improve communication and efficiencies for the community.